TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02293148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Oblong, dull red, film-coated, convex tablets with M400 on one side

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching GSK1278863
Description: A round, biconvex, white film coated tablet as matching placebo for GSK1278863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Moxifloxacin
Description: Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
Study: NCT02635360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Radiation is done for standard clinical care purposes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Radiation is done for standard clinical care purposes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg of chemotherapy drug will be given weekly for 5-6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
Study: NCT02268474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 532nm KTP Laser vs 595nm Pulse Dye Laser
Description: Intervention for the Cutera Excel V system is to cease treatment to any subject that is experiencing any adverse reaction.
Study: NCT00666523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytalgic
Description: 3/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 3/Day
Study: NCT03742284

Intervention type: DEVICE
Group type: OTHER
Intervention: SoftOx Wound Irrigation Solution
Description: The SoftOx Wound Irrigation Solution is a Medical device that contains a combination of hypochlorous acid and acetic acid in purified water. SWIS is primary intended for mechanical irrigation of acute wounds whereas hypochlorous acid acts as a ancillary medicinal (drug) substance with potential antimicrobial effects.~Acute wounds will be rinsed according to protocol and safety (AEs/ADEs/SAEs/SADEs) is the primary objective.
Study: NCT04265313

Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using The Neck Dissection Impairment Index, Modified Constant-Murley Score, Short Form-36 Health Survey version-2.0.
Study: NCT02705287

Intervention type: OTHER
Intervention: Vitamin D dynamics-pregnant
Description: tracer dose of deuterated vitamin D3

Intervention type: OTHER
Intervention: Vitamin D dynamics-nonpregnant
Description: tracer dose of deuterated vitamin D3
Study: NCT01719926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
Study: NCT03296033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
Study: NCT04121195

Intervention type: DRUG
Group type: OTHER
Intervention: Dose escalation
Description: The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
Study: NCT02550470

Intervention type: DEVICE
Intervention: Carbon Dioxide Absorbents
Description: Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.

Intervention type: DEVICE
Intervention: Carbon Dioxide Absorbents
Description: Calcium hydroxide lime is one of the newer clinically available carbon dioxide absorbents and probably considered the current standard of care. It is mainly composed of calcium hydroxide and calcium chloride and contains two setting agents: calcium sulfate and polyvinylpyrrolidine which contribute to the increased hardness and porosity of this absorbent. The most significant advantage of calcium hydroxide lime over other agents is that it is produced without sodium and potassium hydroxide which are strong bases.

Intervention type: DEVICE
Intervention: Micropore SpiraLith
Description: lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.

Intervention type: DRUG
Intervention: Sevoflurane

Intervention type: DRUG
Intervention: Sevoflurane

Intervention type: DRUG
Intervention: Sevoflurane
Study: NCT01706887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Amiloride
Description: only arm of the trial
Study: NCT02098785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine citrate
Description: Oral solution
Study: NCT01310452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: insulin detemir once daily with metformin
Study: NCT02315352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT
Description: L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rac-PZQ ODT
Description: Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-PZQ ODT
Description: L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rac-PZQ ODT
Description: Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cesol®
Description: Cesol® tablet at a dose of 150 mg crushed in water
Study: NCT02071667

Intervention type: OTHER
Intervention: Blood draw
Study: NCT00610103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apomorphine hydrochloride
Description: Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: apomorphine hydrochloride
Description: Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
Study: NCT00210470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRX-2
Description: IRX-2 for 10 days (2 s.c. injections of 1 mL each day) into bilateral mastoid insertion regions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Single i.v. injection of low-dose (300 mg/m2) on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 21 days of oral indomethacin, 25 mg. 3 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 21 days of zinc gluconate (65 mg) as part of an oral multivitamin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 21 days of 20 mg. orally
Study: NCT03503253

Intervention type: DEVICE
Group type: OTHER
Intervention: Interlock-35 Fibered IDC Occlusion System
Description: Use of detachable coil for LAA leak closure

Intervention type: DEVICE
Group type: OTHER
Intervention: Concerto Helix Detachable Coil System
Description: Use of detachable coil for LAA leak closure

Intervention type: DEVICE
Group type: OTHER
Intervention: Azur Peripheral Coil System
Description: Use of detachable coil for LAA leak closure
Study: NCT01008293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: 30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
Study: NCT01003574

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle modification and telephone counseling
Description: A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: lifestyle modification and telephone counseling
Description: Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
Study: NCT02867293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided ascitic fluid drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operative drainage of ascites through small skin incision after induction of anesthesia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Study: NCT00948142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-102
Description: 600 mg BID oral tablets for 10-14 days
Study: NCT01310452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neutral protamine insulin
Description: neutral protamine insulin once daily with metformin
Study: NCT02386397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment

Intervention type: DRUG
Group type: OTHER
Intervention: GEMOX
Description: mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEMOX
Description: mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
Study: NCT02481674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: VX15/2503 (pepinemab) is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
Study: NCT00765206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole/sodium bicarbonate
Description: Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole magnesium (20 mg equivalent)
Description: Single dose of omeprazole magnesium per day for either 1 or 7 days.
Study: NCT04046809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food for special medical purposes: Neurotidine®
Description: Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each patient will be given the bottles for the first 3-month treatment period by the hospital pharmacist and will be asked to return them at the end of the period (3 months). Then the patients will be given the other bottles for the next phase of the study (3 months): these will contain placebo if the patient received Neurotidine® in the first phase of the study and vice versa. Again, the patients will be asked to return after 3 months with the study bottles and will be given the last set of bottles for the final phase of the study (3 months).~Administration at a dosage of 10 ml in the morning.
Study: NCT00871975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urodynamics + TETRA - NIRS
Description: Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
Study: NCT03850756

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.
Study: NCT00948142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg BID oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEM-102
Description: 1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
Study: NCT03850756

Intervention type: DIAGNOSTIC_TEST
Intervention: Early kidney damage biomarkers
Description: In the urine samples of these patients, a series of biomarkers of early kidney damage and / or predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Predisposition to kidney injury biomarkers
Description: In the urine samples of these patients, a series of biomarkers of predisposition to kidney damage will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Tobacco consumption
Description: In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
Study: NCT01476774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Transdermal System
Description: Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Transdermal System
Description: Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.~maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control .
Study: NCT03850756

Intervention type: DIAGNOSTIC_TEST
Intervention: Tobacco consumption
Description: In order to know the degree of tobacco consumption, the biomarker cotinine will be measured in the urine samples of these patients.
Study: NCT04349267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986315
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Specified dose on specified days
Study: NCT03592186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Wisely+
Description: Parenting Wisely+ experimental intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual
Study: NCT04062630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFuse 3-D in Bedrock Configuration
Description: Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed, additionally iFuse 3-D implants are placed in a trajectory parallel to the S2AI screws.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multilevel Lumbar Fusion surgery
Description: Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multilevel Lumbar Fusion surgery
Description: Procedure in which 3 or more spinal segments are fused and concomitant pelvic fixation is performed.
Study: NCT01069003

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Description: Placebo and ASA (75 mg - 325 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thienopyridine Therapy
Description: Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
Study: NCT00451880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL281
Description: Gelatin capsules supplied as 5-, 25-, and 100-mg strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL281
Description: Gelatin capsules supplied as 5-, 25-, and 100-mg strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL281
Description: Gelatin capsules supplied as 5-, 25-, and 100-mg strengths

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: famotidine
Description: single dose, supplied as 20-mg or 40-mg tablets
Study: NCT02435758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preservation of Denonvilliers Fascia during L-PANP surgery
Description: In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
Study: NCT00420433

Intervention type: PROCEDURE
Intervention: Skeletal Scintigraphy
Description: Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
Study: NCT01069003

Intervention type: DEVICE
Group type: OTHER
Intervention: Surveillance Arm
Description: Non randomized arm to understand clinical outcomes in a commercial setting
Study: NCT03944577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Enrolled study participants will be treated with evolocumab (Repatha) 140 mg injected subcutaneously every 2 weeks for 52 weeks. All study participants will receive instruction on correct self-administration by research pharmacists. Study drug will be mailed to patients on a monthly basis for self-administration by patients. The evolocumab dose (140 mg every 2 weeks) will remain constant for the duration of the study. Side effects will be assessed on a quarterly basis. Serious adverse events considered related to treatment, death, and pregnancy will all result in immediate discontinuation of the study drug.
Study: NCT02269969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin